Election 2024 Latest: Trump and Harris work to expand their coalitions in final weeks of election
FBI finds violent crime declined in 2023. Here's what to know about the report
Fed's Goolsbee sees 'many more' rate cuts ahead
Japan's outgoing premier Kishida stresses need for US leadership
Pope Francis has long history of health problems
Harris reaches agreement on transition planning with Biden administration, no word on Trump yet
Stellantis aims to cut North America inventories by 100,000 by early-2025, CFO says
Before you sign up for a store credit card, know what you're getting into
Diddy’s music streams jump after after arrest and indictment
Jeanine Tesori becomes first woman composer to open Met Opera season with reworked `Grounded'
Boise State returns to rankings 3 years after 19-season streak was snapped
(Reuters) -Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan.
The collaboration will help Bristol Myers to expand its manufacturing capacity due to increasing demand. The company said in February it was looking to launch both its CAR-T blood cancer therapies Abecma and Breyanzi in a number of new countries this year.
CAR-T therapy involves removing a patients' own T cells - a key component of the immune system - engineering them to recognize and attack malignant cells, and re-infusing them.
(Reporting by Christy Santhosh; Editing by Shinjini Ganguli)
